DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
RCE
The request filed on 3/30/2026 for a request for continued examination (RCE) under 37 CFR 1.114 (d) is acceptable and a RCE has been established. An action on the RCE follows.
Status of claims
Claims 1-22 are pending.
Claims 1-10 are considered withing the elected species of SEQ ID NOS: 35-36.
Claims 11-20 are withdrawn from consideration.
Terminal Disclaimer
The Terminal Disclaimers
The Terminal Disclaimers filed on 3/30/2026 has been acknowledged and accepted.
Double Patenting
The rejection of Claim 1-10 on the ground of nonstatutory double patenting as being unpatentable over claims 9 and 12 of U.S. Patent No. 10, 828,363 has been removed because the terminal Disclaimer has been filed and accepted, The rejection is removed..
The rejection Claim 1-10 on the ground of nonstatutory double patenting as being unpatentable over claims 9 and 12 of U.S. Patent No. 11, 883, 484 because the terminal Disclaimer has been filed and accepted, The rejection is removed..
Examiner’s note:
It is noted that the nucleic acid sequence of SEQC ID NO: 35 encodes the amino acid sequence of SEQ ID NO; 36. Hence the claimed composition comprising more than two nucleic acid sequences can be considered more than two same kinds of nucleic acid sequences in same or different length.
The citation of optional mean something can be available to be choses but it not mandatory or required in the claimed nucleic acid sequence.
New ground of objection and rejections:
Claim Objections
Claim 1 is objected to because of the following informalities: please correct the typographic error of “like to” as link to. Appropriate correction is required.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claim 1 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 1 is vague and indefinite because it is confusing and unclear how the claimed nucleic acid sequence is optionally like to a nucleic acid sequence encoding an IgE signal peptide?
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 1-8 and 10 are rejected under 35 U.S.C. 102(a) (2) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over US Patent No. 10,953,108 to Ertl et al. and further in view of Yan et al. (Vaccine 2011, Vol. 29, pp. 7173-7181).
Claims 1-8 are directed to A composition comprising two or more nucleic acid molecules encoding an HIV immunogen, wherein each nucleic acid molecule comprises a sequence independently selected from the group consisting of: a nucleic acid sequence encoding protein or fragment thereof to a sequence with at least 90% homology to SEQ ID NO: 36 or a nucleic acid sequence with at least 90% homology to SEQ ID NO: 35, wherein the nucleic acid sequence is “optional” linked a nucleic acid sequence encoding an IgE sequence.
Ertl et al. disclose a nucleotide (FIGS. 24A-24H) and amino acid sequences (FIGS. 24I-43K) encoded by the nucleic acid encoding the same,, wherein the nucleic acid sequence can be carried or expressed by an expression vector , wherein the expression vector can be a carrier AdC6 vector expressing gp160, construct DU172 (SEQ ID NOs: 5 and 13 respectively) or the amino acid sequence of SEQ ID NOS: 13 and 15) see FIGS. 26A-26K are a list of the nucleotide (FIGS. 26A-26H) and amino acid (FIGS. 26I-26K) sequences of the AdC7 vector expressed gp160, construct DU172 . Prior to the HIV antigen is expressed by the adenovirus vector, they are (See FIGS. 19A-19C) are carried by Shuttle plasmids containing gp140 (DU172 and DU422).
In addition, Ertl et al. also teach that the composition of the “nucleic acid molecule’ carried by any expression vector“ is operably linked” sequences include both expression control sequences that are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest. Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation (polyA) signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance secretion of the encoded product. There are numerous expression control sequences, including promoters which are native, constitutive, inducible and/or tissue-specific, are known in the art that may be used in the compositions of the invention. “Operably linked” should be construed to include RNA expression and control sequences in addition to DNA expression and control sequences.
Ertl et al. also teach in one embodiment , the immunogenic composition further comprising an adjuvant (Column 19-column 40). (Please see the SEQ ID NO: 15 and 13 homology alignment
Query Match 100.0%; Score 4574; Length 11142;
Best Local Similarity 100.0%;
Matches 860; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MRVMGILRSYQQWWIWGILGFWMLMICNVWGNLWVTVYYGVPVWKEAKTTLFCASDAKAH 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 404 MRVMGILRSYQQWWIWGILGFWMLMICNVWGNLWVTVYYGVPVWKEAKTTLFCASDAKAH 463
Qy 61 KEEVHNIWATHACVPTDPNPQEIVLKNVTENFNMWKNDMVDQMHEDIISLWDQSLKPCVK 120
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 464 KEEVHNIWATHACVPTDPNPQEIVLKNVTENFNMWKNDMVDQMHEDIISLWDQSLKPCVK 523
Qy 121 LTPLCVTLNCSDVKIKGTNATYNNATYNNNNTISDMKNCSFNTTTEITDKKKKEYALFYK 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 524 LTPLCVTLNCSDVKIKGTNATYNNATYNNNNTISDMKNCSFNTTTEITDKKKKEYALFYK 583
Qy 181 LDVVALDGKETNSTNSSEYRLINCNTSAVTQACPKVSFDPIPIHYCAPAGYAILKCNNKT 240
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 584 LDVVALDGKETNSTNSSEYRLINCNTSAVTQACPKVSFDPIPIHYCAPAGYAILKCNNKT 643
Qy 241 FNGTGPCNNVSTVQCTHGIKPVVSTQLLLNGSLAEEEVVIRFENLTNNAKIIIVHLNESV 300
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 644 FNGTGPCNNVSTVQCTHGIKPVVSTQLLLNGSLAEEEVVIRFENLTNNAKIIIVHLNESV 703
Qy 301 EINCTRPSNNTRKSVRIGPGQTFFATGDIIGDIRQAHCNISRKKWNTTLQRVKEKLKEKF 360
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 704 EINCTRPSNNTRKSVRIGPGQTFFATGDIIGDIRQAHCNISRKKWNTTLQRVKEKLKEKF 763
Qy 361 PNKTIQFAPSSGGDLEITTHSFNCRGEFFYCYTSDLFNSTYMSNNTGGANITLQCRIKQI 420
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 764 PNKTIQFAPSSGGDLEITTHSFNCRGEFFYCYTSDLFNSTYMSNNTGGANITLQCRIKQI 823
Qy 421 IRMWQGVGQAMYAPPIAGNITCKSNITGLLLTRDGGKEKNDTETFRPGGGDMRDNWRSEL 480
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 824 IRMWQGVGQAMYAPPIAGNITCKSNITGLLLTRDGGKEKNDTETFRPGGGDMRDNWRSEL 883
Qy 481 YKYKVVEIKPLGIAPDKAKRRVVEREKRAVGIGAVFLGFLGAAGSTMGAASMTLTVQARQ 540
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 884 YKYKVVEIKPLGIAPDKAKRRVVEREKRAVGIGAVFLGFLGAAGSTMGAASMTLTVQARQ 943
Qy 541 LLSGIVQQQSNLLRAIEAQQHMLQLTVWGIKQLQTRVLAIERYLKDQQLLGIWGCSGKLI 600
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 944 LLSGIVQQQSNLLRAIEAQQHMLQLTVWGIKQLQTRVLAIERYLKDQQLLGIWGCSGKLI 1003
Qy 601 CTTAVPWNASWSNKSYEEIWGNMTWMQWDREINNYTNTIYSLLEESQNQQEKNEKDLLAL 660
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1004 CTTAVPWNASWSNKSYEEIWGNMTWMQWDREINNYTNTIYSLLEESQNQQEKNEKDLLAL 1063
Qy 661 DSWESLWSWFNITNWLWYIRIFIIIVGGLIGLRIIFAVLSIVNRVRQGYSPLSFQTLTPS 720
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1064 DSWESLWSWFNITNWLWYIRIFIIIVGGLIGLRIIFAVLSIVNRVRQGYSPLSFQTLTPS 1123
Qy 721 PREPDRLGRIEEEGGEQDRARSVRLVNGFLALAWEDLRSLCLFSYHRLRDLILIAARAAA 780
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1124 PREPDRLGRIEEEGGEQDRARSVRLVNGFLALAWEDLRSLCLFSYHRLRDLILIAARAAA 1183
Qy 781 LLGRSSLWGLQKGWEALKYLGSLVQYWGLELKKSAISLFDAIA ITVAEGTDRIINIVQRI 840
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1184 LLGRSSLWGLQKGWEALKYLGSLVQYWGLELKKSAISLFDAIA ITVAEGTDRIINIVQRI 1243
Qy 841 SRAFYNIPRRIRQGFEATLQ 860
||||||||||||||||||||
Db 1244 SRAFYNIPRRIRQGFEATLQ 1263
Or Qy 1 ATGAGAGTGATGGGGATTCTGAGGTCCTATCAGCAGTGGTGGATCTGGGGGATTCTGGGA 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 404 MetArgValMetGlyIleLeuArgSerTyrGlnGlnTrpTrpIleTrpGlyIleLeuGly 423
Qy 61 TTCTGGATGCTGATGATTTGTAATGTCTGGGGCAACCTGTGGGTGACCGTCTACTATGGG 120
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 424 PheTrpMetLeuMetIleCysAsnValTrpGlyAsnLeuTrpValThrValTyrTyrGly 443
Qy 121 GTGCCTGTCTGGAAGGAGGCCAAAACCACACTGTTCTGCGCTTCCGACGCCAAGGCTCAT 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 444 ValProValTrpLysGluAlaLysThrThrLeuPheCysAlaSerAspAlaLysAlaHis 463
Qy 181 AAAGAGGAAGTCCATAACATCTGGGCAACACACGCCTGTGTGCCAACTGATCCAAACCCC 240
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 464 LysGluGluValHisAsnIleTrpAlaThrHisAlaCysValProThrAspProAsnPro 483
Qy 241 CAGGAGATTGTGCTGAAGAATGTCACCGAAAACTTCAACATGTGGAAGAACGACATGGTG 300
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 484 GlnGluIleValLeuLysAsnValThrGluAsnPheAsnMetTrpLysAsnAspMetVal 503
Qy 301 GATCAGATGCATGAGGACATCATTTCTCTGTGGGATCAGAGTCTGAAGCCTTGCGTGAAA 360
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 504 AspGlnMetHisGluAspIleIleSerLeuTrpAspGlnSerLeuLysProCysValLys 523
Qy 361 CTGACACCACTGTGCGTCACTCTGAACTGTTCTGACGTGAAGATCAAAGGCACAAATGCC 420
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 524 LeuThrProLeuCysValThrLeuAsnCysSerAspValLysIleLysGlyThrAsnAla 543
Qy 421 ACTTACAACAACGCTACCTACAACAACAACAACACAATCAGTGACATGAAGAACTGTTCA 480
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 544 ThrTyrAsnAsnAlaThrTyrAsnAsnAsnAsnThrIleSerAspMetLysAsnCysSer 563
Qy 481 TTCAATACTACCACAGAGATCACCGATAAGAAAAAGAAAGAATACGCACTGTTTTATAAG 540
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 564 PheAsnThrThrThrGluIleThrAspLysLysLysLysGluTyrAlaLeuPheTyrLys 583
Qy 541 CTGGACGTGGTCGCCCTGGATGGAAAAGAGACCAACAGCACAAATAGCTCCGAATACCGG 600
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 584 LeuAspValValAlaLeuAspGlyLysGluThrAsnSerThrAsnSerSerGluTyrArg 603
Qy 601 CTGATCAACTGCAATACTAGTGCAGTCACCCAGGCCTGTCCCAAGGTGTCATTCGATCCT 660
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 604 LeuIleAsnCysAsnThrSerAlaValThrGlnAlaCysProLysValSerPheAspPro 623
Qy 661 ATCCCAATTCACTACTGCGCACCTGCCGGCTATGCCATCCTGAAGTGTAACAACAAGACC 720
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 624 IleProIleHisTyrCysAlaProAlaGlyTyrAlaIleLeuLysCysAsnAsnLysThr 643
Qy 721 TTCAACGGGACTGGACCATGCAACAATGTGAGCACCGTCCAGTGTACACATGGGATCAAG 780
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 644 PheAsnGlyThrGlyProCysAsnAsnValSerThrValGlnCysThrHisGlyIleLys 663
Qy 781 CCCGTGGTCTCCACCCAGCTGCTGCTGAACGGATCTCTGGCTGAGGAAGAGGTGGTCATT 840
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 664 ProValValSerThrGlnLeuLeuLeuAsnGlySerLeuAlaGluGluGluValValIle 683
Qy 841 AGGTTCGAGAATCTGACAAACAATGCCAAGATCATTATCGTGCACCTGAACGAGTCCGTC 900
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 684 ArgPheGluAsnLeuThrAsnAsnAlaLysIleIleIleValHisLeuAsnGluSerVal 703
Qy 901 GAAATCAATTGCACTCGCCCAAGCAACAATACCAGAAAATCCGTGAGGATTGGCCCCGGG 960
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 704 GluIleAsnCysThrArgProSerAsnAsnThrArgLysSerValArgIleGlyProGly 723
Qy 961 CAGACTTTCTTTGCTACCGGCGACATTATCGGGGATATCAGACAGGCACATTGTAACATT 1020
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 724 GlnThrPhePheAlaThrGlyAspIleIleGlyAspIleArgGlnAlaHisCysAsnIle 743
Qy 1021 TCTAGGAAGAAATGGAACACTACCCTGCAGCGGGTGAAGGAGAAACTGAAGGAAAAATTC 1080
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 744 SerArgLysLysTrpAsnThrThrLeuGlnArgValLysGluLysLeuLysGluLysPhe 763
Qy 1081 CCCAACAAGACTATCCAGTTTGCCCCTTCTAGTGGCGGGGACCTGGAGATTACAACTCAC 1140
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 764 ProAsnLysThrIleGlnPheAlaProSerSerGlyGlyAspLeuGluIleThrThrHis 783
Qy 1141 AGCTTCAATTGCAGAGGCGAATTCTTTTACTGTTATACATCCGATCTGTTTAACAGCACA 1200
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 784 SerPheAsnCysArgGlyGluPhePheTyrCysTyrThrSerAspLeuPheAsnSerThr 803
Qy 1201 TACATGTCCAACAATACTGGAGGCGCTAATATCACCCTGCAGTGCCGGATTAAGCAGATT 1260
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 804 TyrMetSerAsnAsnThrGlyGlyAlaAsnIleThrLeuGlnCysArgIleLysGlnIle 823
Qy 1261 ATCAGAATGTGGCAGGGAGTGGGCCAGGCTATGTATGCACCCCCTATCGCCGGAAACATT 1320
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 824 IleArgMetTrpGlnGlyValGlyGlnAlaMetTyrAlaProProIleAlaGlyAsnIle 843
Qy 1321 ACCTGTAAATCCAATATCACCGGACTGCTGCTGACACGCGACGGAGGAAAGGAGAAAAAC 1380
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 844 ThrCysLysSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyLysGluLysAsn 863
Qy 1381 GATACTGAAACCTTTCGACCAGGAGGAGGAGACATGCGAGATAATTGGCGATCTGAGCTG 1440
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 864 AspThrGluThrPheArgProGlyGlyGlyAspMetArgAspAsnTrpArgSerGluLeu 883
Qy 1441 TACAAGTATAAAGTGGTCGAAATCAAGCCACTGGGCATTGCTCCCGACAAGGCAAAACGG 1500
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 884 TyrLysTyrLysValValGluIleLysProLeuGlyIleAlaProAspLysAlaLysArg 903
Qy 1501 AGAGTGGTCGAGCGGGAAAAAAGAGCAGTGGGGATCGGAGCCGTCTTCCTGGGCTTTCTG 1560
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 904 ArgValValGluArgGluLysArgAlaValGlyIleGlyAlaValPheLeuGlyPheLeu 923
Qy 1561 GGAGCAGCTGGATCTACCATGGGAGCAGCCAGTATGACACTGACTGTGCAGGCCAGGCAG 1620
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 924 GlyAlaAlaGlySerThrMetGlyAlaAlaSerMetThrLeuThrValGlnAlaArgGln 943
Qy 1621 CTGCTGTCAGGGATCGTGCAGCAGCAGAGCAACCTGCTGCGCGCCATTGAGGCTCAGCAG 1680
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 944 LeuLeuSerGlyIleValGlnGlnGlnSerAsnLeuLeuArgAlaIleGluAlaGlnGln 963
Qy 1681 CATATGCTGCAGCTGACAGTGTGGGGGATCAAGCAGCTGCAGACTAGGGTGCTGGCCATT 1740
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 964 HisMetLeuGlnLeuThrValTrpGlyIleLysGlnLeuGlnThrArgValLeuAlaIle 983
Qy 1741 GAACGCTACCTGAAGGACCAGCAGCTGCTGGGCATCTGGGGGTGCTCTGGAAAACTGATT 1800
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 984 GluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGlyLysLeuIle 1003
Qy 1801 TGTACCACAGCTGTGCCTTGGAACGCATCCTGGTCTAATAAGAGTTATGAAGAGATCTGG 1860
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1004 CysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerTyrGluGluIleTrp 1023
Qy 1861 GGCAACATGACCTGGATGCAGTGGGATAGGGAGATCAACAATTACACCAATACAATCTAC 1920
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1024 GlyAsnMetThrTrpMetGlnTrpAspArgGluIleAsnAsnTyrThrAsnThrIleTyr 1043
Qy 1921 TCACTGCTGGAAGAGAGCCAGAACCAGCAGGAGAAGAATGAAAAAGACCTGCTGGCTCTG 1980
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1044 SerLeuLeuGluGluSerGlnAsnGlnGlnGluLysAsnGluLysAspLeuLeuAlaLeu 1063
Qy 1981 GATAGTTGGGAGTCACTGTGGAGCTGGTTCAACATCACAAATTGGCTGTGGTACATCAGG 2040
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1064 AspSerTrpGluSerLeuTrpSerTrpPheAsnIleThrAsnTrpLeuTrpTyrIleArg 1083
Qy 2041 ATCTTCATCATCATTGTGGGCGGGCTGATCGGACTGCGCATCATTTTCGCCGTGCTGTCA 2100
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1084 IlePheIleIleIleValGlyGlyLeuIleGlyLeuArgIleIlePheAlaValLeuSer 1103
Qy 2101 ATTGTGAACCGAGTCCGGCAGGGCTATTCCCCTCTGTCTTTTCAGACTCTGACCCCCAGC 2160
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1104 IleValAsnArgValArgGlnGlyTyrSerProLeuSerPheGlnThrLeuThrProSer 1123
Qy 2161 CCTAGAGAGCCAGACAGGCTGGGGCGCATCGAAGAGGAAGGAGGCGAACAGGATAGAGCC 2220
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1124 ProArgGluProAspArgLeuGlyArgIleGluGluGluGlyGlyGluGlnAspArgAla 1143
Qy 2221 AGGAGCGTGCGGCTGGTCAATGGATTCCTGGCTCTGGCATGGGAGGACCTGAGATCCCTG 2280
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1144 ArgSerValArgLeuValAsnGlyPheLeuAlaLeuAlaTrpGluAspLeuArgSerLeu 1163
Qy 2281 TGCCTGTTTTCTTACCACCGCCTGCGAGATCTGATCCTGATTGCTGCACGAGCCGCTGCA 2340
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1164 CysLeuPheSerTyrHisArgLeuArgAspLeuIleLeuIleAlaAlaArgAlaAlaAla 1183
Qy 2341 CTGCTGGGACGGTCAAGCCTGTGGGGACTGCAGAAGGGCTGGGAGGCCCTGAAATACCTG 2400
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1184 LeuLeuGlyArgSerSerLeuTrpGlyLeuGlnLysGlyTrpGluAlaLeuLysTyrLeu 1203
Qy 2401 GGGAGTCTGGTGCAGTATTGGGGACTGGAACTGAAGAAAAGTGCCATCTCACTGTTCGAC 2460
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1204 GlySerLeuValGlnTyrTrpGlyLeuGluLeuLysLysSerAlaIleSerLeuPheAsp 1223
Qy 2461 GCCATCGCTATTACTGTGGCTGAGGGCACCGATCGGATCATTAACATCGTGCAGCGAATT 2520
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1224 AlaIleAlaIleThrValAlaGluGlyThrAspArgIleIleAsnIleValGlnArgIle 1243
Qy 2521 AGCCGGGCATTCTACAATATCCCCAGGCGCATTAGACAGGGGTTTGAAGCCACCCTGCAG 2580
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1244 SerArgAlaPheTyrAsnIleProArgArgIleArgGlnGlyPheGluAlaThrLeuGln 1263
Because the nucleic acid molecule encoding an IgE signal peptide is only cited as an optional , the cited reference anticipates claims 1-8 and 10.
who teach incorporating an IgE leader sequence into the new DNA vaccine construct, In this study, they designed a clade C env gene (EY3E1-C) to decrease the genetic distances of virus isolates within clade C and focus the induced T cell responses to conserved clade C epitopes. After generating a consensus sequence by analyzing full-length clade C env early transmitter sequences, several modifications were performed to increase the expression of the EY3E1-C, including codon/RNA optimization, addition of Kozak sequence and addition of an IgE leader sequence. The cellular immune responses of pEY3E1-C could be further enhanced when the DNA was delivered by using electroporation (EP). Thus, the synthetic engineered consensus EY3E1-C gene is capable of elicit ing stronger and broader CTL responses than primary clade C envelopes. This finding suggests that such synthetic immunogens could be important for examination of their potential as part of an efficient HIV DNA vaccine.
Or alternately, in light of teaching by Yan et al. described above to be motivated by combining the teaching from Ertl et al. and Yan tet al to make a better HIV immunogenic composition comprising the more optimal DNA expression construct via cooperating the IgE signal peptide for further enhance the recombinant antigen expression and also suitable for DNA plasmid delivered by electroporation (EP) with a reasonable expectation of success.
As there are no unexpected results have been provided, hence the claimed invention as a whole is prima facie obvious absence unexpected results.
PNG
media_image1.png
478
895
media_image1.png
Greyscale
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to BAO Q LI whose telephone number is (571)272-0904. The examiner can normally be reached M-F 8 am to 8 pm EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Allen can be reached at 571-270-3497. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
BAO Q. LI
Examiner
Art Unit 1671
/BAO Q LI/Primary Examiner, Art Unit 1671